Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated W… (NCT00770835) | Clinical Trial Compass
CompletedPhase 4
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
Italy39 participantsStarted 2009-03
Plain-language summary
The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.
Who can participate
Age range40 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Females must be non-pregnant, non-lactating and post-menopausal.
* A glycosylated hemoglobin level greater than 7.5% and less than 10%.
* Has an age of onset of Type 2 Diabetes greater than 35 years of age.
* Is on metformin monotherapy up to the maximum tolerated daily dose.
* Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.
* Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.
* Has one or more cardiovascular comorbidities as follows:
* stable angina pectoris
* previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography
* peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.
* and/or two or more of the following major cardiovascular risk factors:
* hypertension (blood pressure \>130/80 mmHg or treatment)
* dyslipidemia (low-density lipoprotein-cholesterol \>100 mg/dl or treatment and/or high-density lipoprotein-cholesterol \<40 mg/dl in men and \<45 mg/dl in women or treatment)
* smoking (\>10 cigarettes/day)
Exclusion Criteria:
* Has Type 1 Diabetes.
* Is on insulin therapy.
* Is severely obese defined as a body mass ind…
What they're measuring
1
Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).